Results from Phase I
![ASCO 2023: Promising Results from Phase I Study of Sleeping Beauty TCR-T Cells Targeting Shared KRAS and TP53 Mutations in Solid Tumors](https://pharmtales.com/wp-content/uploads/2023/06/ASCO-2023Promising-Results-from-Phase-I-Study-of-Sleeping-Beauty-TCR-T-Cells-Targeting-Shared-KRAS-and-TP53-Mutations-in-Solid-Tumors.jpg)
ASCO 2023: Promising Results from Sleeping Beauty TCR-T Cells
SG Tylor
ABSTRACT NUMBER – 2547 Alaunos’ Clinical TCR Library focuses on targeting the most common mutations found in KRAS, TP53, and ...
ABSTRACT NUMBER – 2547 Alaunos’ Clinical TCR Library focuses on targeting the most common mutations found in KRAS, TP53, and ...